PharmAsia News from Elsevier Business Intelligence

Japan To Push For Cervical Cancer, Pediatric Pneumococcal and Influenza Vaccines

Tue, 29 May 2012 13:35:57 -0400

Japan’s Subcommittee of the Infectious Disease Group Health Science Council decided on May 23 to prioritize bills for cervical cancer, pediatric pneumococcal and influenza vaccinations.

Nipro Pharma And Sandoz Co-market Somatropin

Tue, 29 May 2012 13:34:02 -0400

Nipro Pharma and Sandoz will publish information in Japan about Somatropin BS S.C. Injection.

Takeda Submits NDA To EMA For Second-Gen Actos

Tue, 29 May 2012 13:30:57 -0400

Takeda Pharmaceuticals submits application to the EMA for next-generation Actos product.

Japanese Pharma Companies Open Public Recruiting

Tue, 29 May 2012 13:28:20 -0400

Shionogi Pharmaceuticals is one of several major pharmaceutical companies to begin publicizing cooperative research.

Takeda Pharmaceuticals Acquites Brazil’s Multilab To Boost Ex-Japan Sales

Tue, 29 May 2012 13:26:48 -0400

Takeda Pharmaceuticals announced the purchase of the mid-sized Brazilian pharmaceutical company Multilab for ¥20 billion on May 25.

Pakistan Drug Makers Call For More Predictable Regulatory Process

Tue, 29 May 2012 13:02:44 -0400

Pakistan's drug makers, including multinational firms, are appealing to the government to adopt a pricing mechanism they can count on in planning future investments.

Piramal Bucks Pharma Trend By Investing Heavily In Cheaper R&D Try

Tue, 29 May 2012 12:38:38 -0400

Piramal Healthcare is bucking an international pharmaceutical industry trend by plunging into the drug-discovery business to prove the process can be done more cheaply.

Lilly, Merck, Pfizer-Funded Research Cites Hep B Virus In Liver Cancer

Tue, 29 May 2012 12:36:49 -0400

Singapore researchers, jointly funded by Lilly, Merck and Pfizer, said a study of 88 Hong Kong liver patients who had surgery or transplants identified the hepatitis B virus as a contributor.

Ranbaxy, Dr. Reddy's To Benefit From Teva Skipping U.S. Lipitor Market

Tue, 29 May 2012 12:33:07 -0400

Ranbaxy Laboratories and Dr. Reddy's Laboratories can expect a greater share of the U.S. market for a generic of Pfizer Inc.'s Lipitor (atorvastatin) after Teva Pharmaceuticals said it would shun that market.

China Device Market At $63.3 Billion, Growing 20% A Year

Tue, 29 May 2012 12:30:38 -0400

China's medical-device market is estimated at $63.3 billion and growing by 20% annually, according to the head of the Chinese Society of Biomedical Engineering.

China SFDA Mulls Preferential Treatment For Makers Of Pediatric Drugs

Tue, 29 May 2012 12:22:33 -0400

China's State FDA is considering providing easier market access to makers of drugs aimed at children as one way to promote a type of drug mostly non-existent in the country.

Do China Start-ups Differ From The West?

j.berlin@elsevier.com — Tue, 29 May 2012 12:16:07 -0400

During the annual ChinaBio conference in Shanghai, four top start ups – Ascletis, Aslan, BeiGene and Hua Medicine – discuss how their strategies in China differ from the traditional U.S. biotech model.

India Lags China In Regional GMP Harmonization – ISPE Singapore

pharmasia@elsevier.com — Tue, 29 May 2012 11:33:09 -0400

China is actively seeking to enter a global agreement on good manufacturing processes for drugs while India remains aloof from a growing Asia movement on harmonization for inspections, training and rules in the industry.

India May Go For Reference Pricing As Negotiated Pricing May Endanger Compulsory License Policy

v.dandekar@elsevier.com — Tue, 29 May 2012 11:08:06 -0400

Reference pricing leaves room for scaling down prices via compulsory licenses.

Hong Kong and Australia Biotech Groups Boost Cooperation

pharmasia@elsevier.com — Mon, 28 May 2012 04:00:00 -0400

The two groups hope member companies will benefit from Australia's expertise and Hong Kong's start-up scene.

Japan Reports Halving Of Meningitis Cases In Under-Five Kids Given Shots